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Human C5a des arg was isolated from complement-activated serum by immunoadsorption followed 
by Sephadex G-75 chromatography. C5a des arg obtained by this 2-step procedure was shown to be 
immunologically identical to C5a des arg purified by a conventional multi-step method, homogeneous on 
SDS-polyacrylamide gels, and biologically active. Although this technique yields approximately the same 
amount of C5a des arg/liter of activated serum as that obtained by conventional methods, its simplicity 
and relative rapidity make it a practical alternative. 
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Introduction 
Activation of complement by either the classical or alternate pathway generates 
peptides with diverse biological activities. The C5a molecule, generated from com- 
plement component C5, has a variety of important phlogistic activities including: 
contraction of smooth muscle, histamine release from mast cells, increased vascular 
permeability (Cochrane and Mialler-Eberhard, 1968; Shin et al., 1968; Vogt, 1968), 
leukocyte chemotaxis (Ward and Newman, 1969; Chenoweth and Hugli, 1980), 
lysosomal enzyme secretion (Goldstein et al., 1973; Goldstein and Weissmann, 1974; 
Henson et al., 1978), leuko-aggregation (Craddock et al., 1977), and stimulation of 
leukocytic oxidative metabolism (Goetzl et al., 1974; Goldstein et al., 1975). How- 
ever, carboxypeptidase activity present in serum rapidly cleaves the COOH-terminal 
arginine from C5a (Bokisch et al., 1969) and destroys virtually all of its anaphylactic 
function (Bokisch and Mtiller-Eberhard, 1970). The resulting peptide, C5a des arg, 
retains most other pro-inflammatory activities and is the predominant form of the 
C5 fragment found in complement-activated serum. 
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Both human C5a and C5a des arg have been purified to homogeneity and well 
characterized chemically (Fernandez and Hugli, 1976; Fernandez and Hugli, 1978: 
Gerard and Hugli, 1981). For most studies involving the biological activities of ( '5a 
and C5a des arg complement-activated serum or serum fractions are used. Conse- 
quently it has been difficult to rule out the contribution of other serum proteins on 
the observed phenomena. In this report we describe a purification scheme for 
isolating milligram quantities of highly purified C5a des arg from complement- 
activated human serum using immunoadsorbent  and molecular sieve chromatogra- 
phy. This procedure is simpler and faster than conventional purification procedures 
(Vallota and Miiller-Eberhard, 1973: Fernandez and Hugli, 1976; Fernandez and 
Hugli, 1978) and thus provides a practical alternative. 
Materials and Methods 
Preparation of human leuko~Ttes 
Leukocytes from healthy volunteers were isolated by dextran sedimentation using 
blood to which sodium heparin had been added (Manderino et al., 1981). 
Preparation of serum 
Outdated plasma was obtained from a local blood bank, converted to serum, and 
processed to remove clots and lipids as previously described (Manderino et al., 
1981). 
Antiserum production 
Human C5a des arg was purified from serum by the method of Vallota and 
Mtiller-Eberhard (1973). Antibodies to C5a des arg were raised in a goat by multisite 
intramuscular injections of 50 jag of C5a des arg emulsified in complete Freund's 
adjuvant. The goat was boosted at 4 month intervals. Antiserum was collected 10 
days after each C5a des arg injection and IgG was isolated according to the method 
of Gray et al. (1969). 
Preparation of immunoadsorbent columns 
The IgG fraction of goat anti-C5a des arg was incubated with 200 ml of 
CNBr-activated Sepharose 6B (10.2 mg I g G / m l  Sepharose) overnight at 4°C 
(Cuatrecasas et al., 1968). The extent of coupling was determined to be 9.8 mg 
I g G / m l  Sepharose 4B. The slurry was poured into a 5 mm × 70 mm column and 
equilibrated with phosphate-buffered saline. 
Isolation of C5a des arg 
Six liters of normal human serum were incubated at 37°C for 60 min with boiled 
yeast cells (20 g / l )  to activate complement (Vallota and Mtiller-Eberhard, 1973). The 
yeast was removed by centrifugation (400 X g for 10 min) and the serum was 
heat-inactivated for 30 min at 56°C. The activated serum was applied to the 
Sepharose 6B anti-C5a des arg column at a flow rate of 100 m l / h  at 4°C. The 
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column was washed with 2 liters of PBS and the adsorbed material was eluted with 
0.2 M glycine-HC1 buffer, pH 2.8. After dialysis in PBS the eluate was concentrated 
to 6 ml using YM5 ultrafiltration (Amicon, Lexington, MA). Five milliliters of this 
concentrate were then applied to a 2.5 cm × 93 cm Sephadex G-75 column calibrated 
with various molecular weight markers and eluted with PBS (8 ml/h).  Fractions 
demonstrating chemotactic activity (~  10-15,000 daltons) were pooled and con- 
centrated by YM5 ultrafiltration. 
Chemotaxis assay 
Chemotaxis by human neutrophils under agarose was assayed as previously 
described (Manderino et al., 1981). In this assay, neutrophil migration distances in 
the presence or absence of chemoattractant were quantitated. Results were expressed 
as the chemotactic index (CI), i.e. A/B,  where A represents directed migration and B 
represents random migration. In the absence of a chemotactic gradient the CI is 
unity. CI values greater than one are obtained in the presence of a chemotactic 
gradient. 
Lysosomal enzyme releasing activity 
Lysosomal enzyme release from human neutrophils was assessed by a modifica- 
tion of the procedure of Fantone et al. (1979). Two hundred microliters of human 
neutrophils (2 × 10 v cells/ml) in Hanks' balanced salt solution containing 0.1% 
(w/v)  bovine serum albumin and 5 /~g/ml cytochalasin B (Aldrich Chemical Co., 
Milwaukee, WI) were added to tubes containing 40/~1 of C5a des arg or saline. After 
incubating for 10 rain at 37°C the mixtures were centrifuged at 200 × g for 10 rain at 
4°C. N-acetyl-/~-glucosaminidase activity was assayed by incubating 50/~1 of super- 
natant with 450 /~1 of 4mM p-nitrophenyl-N-acetyl-B-D-glucosaminide (Sigma 
Chemical Co., St. Louis, MO) in 0.05 M sodium citrate buffer for 2 h at 37°C. The 
reaction was terminated by the addition of 500/~1 glycine-NaOH buffer (0.4 M, pH 
10.5) and absorbance was measured at 410 nm. 
SDS-PA GE 
Analysis by SDS-polyacrylamide gel electrophoresis was performed using 7.5% 
cylindrical gels and the Weber and Osborn method (1969) under non-reducing 
conditions. Electrophoresis was performed at 7.5 mA/gel  for 4 h at room tempera- 
ture. Gels were subsequently stained for protein using Coomassie blue or for 
carbohydrate using the PAS procedure as described by Segrest et al. (1971). 
Immunochemical analysis 
Ouchterlony immunodiffusion was performed in 1% agarose gels in PBS, pH 7.5. 
Five micrograms of antigen or 75/~g of goat anti-human C5a des arg were added to 
7/~1 wells and incubated for 24 h at room temperature. Immunoelectrophoresis was 
performed in 1% agarose in 0.04M barbital buffer, pH 8.6, employing 5 ~g of 
antigen in 7/~1 wells and developed with 100/~1 of goat anti-human C5a des arg IgG 
(10 mg/ml).  Human C5a des arg was prepared according to the method of Vallota 
and Maller-Eberhard (1973) and human C5 was purified as previously described 
(Kunkel et al., 1980). 
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Protein determinations 
Protein concentrations were determined by absorption at 280 nm and by a 
dye-binding assay (Bio-Rad Laboratories Richmond, CA) using bovine gamma- 
globulin as the standard. 
Results 
Purification of C5a des arg 
Six liters of complement-activated serum were passed over a column containing 
200 ml of Sepharose anti-human C5a des arg. Monitored by its ability to stimulate 
neutrophil chemotaxis, C5a des arg was completely removed from the serum eluted 
from the immunoadsorbent.  The serum fraction adsorbed to the column was 
subsequently eluted with glycine-HC1 buffer. This material was dialyzed vs. PBS, 
concentrated by ultrafiltration and chromatographed on Sephadex G-75. As shown 
in Fig. 1, most of the protein eluted from this column in the 'fall through' region 
( ~  75,000 daltons) (peak I). Smaller peaks eluted in the region of 43,000 daltons 
(peak II) and 15,000 regions (peak III). 
Each Sephadex G-75 fraction was analyzed for chemotactic activity to indicate 
the presence of C5a des arg. Only fractions in peak III  exhibited significant activity 
(Fig. 1). Fractions in each of the 3 peaks were pooled and concentrated. Serial 
dilutions of these samples were assayed for C5a des arg-activity using both che- 
motaxis and induction of neutrophil lysosomal enzyme secretion. As summarized in 
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Fig. l. Sephadex G-75 chromatography of the C5a des arg-enriched fraction obtained from complement- 
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a Buffer (Hanks' balanced salt solution), heat-inactivated normal human serum, and heat-inactivated 
yeast cell-activated human serum were used without dilution. All other reagents were adjusted to 100 
/xg/ml. 
b Means of triplicate determinations from 3 experiments with standard deviations of ~2%. 
c Means of quadruplicate determinations from a representative experiment with standard deviations of 
~10%. 
Tab le  I, on ly  peak  I I I  demons t r a t ed  these biological  activit ies associa ted  with C5a 
des arg. Peak I I I  will subsequent ly  be referred to as i m m u n o a d s o r b e n t - p u r i f i e d  C5a 
des arg. 
Immunochemical analys& of immunoadsorbent-purified C5a des arg 
I m m u n o a d s o r b e n t - p u r i f i e d  C5a des arg showed a line of  ident i ty  with human  C5a 
des arg pur i f ied  by  the me thod  of  Val lo ta  and  Mfi l l e r -Eberhard  (1973) when tested 
with  goat  an t i -human  C5a des arg by  Ouchte r lony  immunod i f fus ion  (Fig. 2). It is 
in teres t ing  to note  that  an t i -C5a des arg d id  not  react  with pur i f ied C5 p repa red  by  
the me thod  of  Kunke l  et al. (1980). N o t  surprisingly,  an t i -C5a des arg did  react  with 
C5a pur i f ied  f rom zymosan-ac t iva ted  h u m a n  serum in the presence of  epsi lon amino  
capro ic  acid  (Val lo ta  and Mii l le r -Eberhard ,  1973). In  IEP  exper iments ,  i m m u n o a d -  
so rben t -pur i f i ed  C5a des arg exhibi ted  s imilar  e lec t rophore t ic  mobi l i ty  as conven-  
t ional ly  pur i f ied  C5a des arg as revealed with an t i -human  C5a des arg (Fig. 3). 
In  add i t i on  to lacking biological  activity,  neither,  peak  I nor  peak  II was react ive 
wi th  an t i -C5a  des arg in Ouchte r lony  and IEP analyses.  Subsequent  analysis  of  these 
peaks  by IEP using an t i -human  serum revealed the presence of a total  of  5 proteins.  
Us ing  a pane l  of ant isera  to var ious  h u m a n  serum proteins ,  two have been ident i f ied,  
i.e. a lbumin  and  IgG.  
SDS-PA GE of immunoadsorbent-purified C5a des arg 
SDS-po lyac ry l amide  gel e lec t rophores is  was employed  to de te rmine  the pur i ty  of 
i m m u n o a d s o r b e n t - p u r i f i e d  C5a des arg. As  shown in  Fig. 4, i m m u n o a d s o r b e n t - p u r i -  
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Fig. 2. Ouchterlony analysis of immunoadsorbent-purified human C5a des arg. Well no. 1, C5a prepared 
according to the method Vallota and M~ller-Eberhard (1973); well no. 2, immunoadsorbent-purified C5a 
des arg; well no. 3, human C5; well no. 4, goat anti-human C5a des arg (lgG). 
fied C5a des arg d i sp layed  a single band  in 7.5% SDS-po lyac ry l amide  gels and  
s ta ined  for bo th  ca rbohyd ra t e  and protein.  The  molecu la r  weight was es t imated  
us ing the me thod  of Segrest and  Jackson  (1972) to be 14,600 dal tons.  
Yield of immunoadsorbent-purified C5a des arg 
The yield of C5a  des arg at  each pur i f ica t ion  step as appra i sed  by chemotac t ic  
act ivi ty  as well as lysosomal  secret ion of B-D-glucosaminidase  is summar ized  on 
Tab le  II. Twenty  six percent  of the chemotac t ic  act ivi ty and 22% of the lysosomal  
secret ion act ivi ty  present  in complemen t -ac t iva t ed  serum remained  in the pur i f ied 
C5a des arg p repara t ion .  The la t ter  f ract ion was concen t ra ted  by ul t raf i l t ra t ion  to 
6 ml. The final p ro te in  concen t ra t ion  was 0.94 m g / m l  as de te rmined  by a dye-b ind-  
ing assay and  0.68 O.D.  u n i t s / m l  as observed at 280 nm spec t rophotomet r ica l ly .  
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Fig. 3. Immunoelectrophoresis of immunoadsorbent-purif ied C5a des arg (top) and C5a des arg prepared 
as described by Vallota and M011er-Eberhard (1973) (bottom) developed with goat ant i -human C5a des 
arg (IgG). 
TABLE II 
S U M M A R Y  OF C5A DES A R G  PURIFICATION 
Purification Total Total Biological activity 
step vol absorbance 
(ml) (280 nm) Chemotaxis a Lysosomal enzyme 
secretion b 
Total Yield Total Yield 
activity (%) activity (%) 
Complement-activated 
serum 6 000 360 000 6 000 100 9 000 100 
Immunoadsorbed 
fraction 260 26.5 2080 35 2600 29 
Sephadex G-75 45 4.2 1 575 26 2000 22 
a Total activity is equal to the reciprocal of the dilution which elicits chemotactic indices of >4.5 
multiplied by the total volume. 
b Lysosomal enzyme secretion was determined by measuring lysosomal enzyme secretion of B-D-glucos- 
aminidase. The total activity was determined by multiplying the dilution giving >~0.3 O.D. 410 nm 
absorbance by the total volume.  
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Fig. 4. SDS-polyacrylamide gel (7.5%) analysis of immunoadsorbent-purified C5a des arg. A: standards 
stained for protein, (1) transferrin, 90,000 daltons; (2) ovalbumin, 43,000 daltons; (3) ribonuclease A, 
13,700 daltons. B: C5a des arg stained for carbohydrate. C: C5a des arg stained for protein. Twenty 
micrograms of C5a were applied to 100 mm• 5 mm gels. 
Discussion 
A combinat ion  of immunoadsorben t  and molecular sieve chromatography  has 
been employed to provide a rapid and simplified method for isolating milligram 
quantities of highly purified and biologically active human  C5a des arg. Although 
other purification schemes have been described for isolating C5a and C5a des arg 
from complement-act ivated serum (Vallota and Mtiller-Eberhard, 1973; Fernandez 
and Hugli, 1976; Fernandez  and Hugli, 1978) these methods are t ime-consuming 
and laborious. The method of Fernandez  and Hugli (1978) for purifying C5a des arg 
f rom activated human  serum, for example, involves 3 chromatographic  columns, an 
acid and an ethanol extraction, 3 dialyses, and 2 lyophilizations. 
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The C5a des arg purified by the simplified procedure described in this report was 
shown to be immunologically identical to C5a des arg purified by a conventional 
method (Vallota and Mt~ller-Eberhard, 1973). In addition, the final preparation 
induced biological activities characteristic of C5a des arg, i.e., induction of neu- 
trophil chemotaxis and lysosomal enzyme secretion. Twenty-six percent of the 
chemotactic activity and 22% of the lysosomal enzyme glucosaminidase secretion 
activity present in complement-activated serum was recovered in the purified C5a 
des arg fraction. Fernandez and Hugli (1978) have estimated that C5a des arg is 
present at 3.3 mg/ l i ter  in activated serum. Our purified C5a des arg preparation 
contained 5.6 mg protein from 6 liters of complement-activated serum representing a 
28% yield, which is in close agreement with the yields calculated on the basis of 
functional activity (Table II). The good correlation between the yields of biological 
activity and protein indicates that the acidic conditions used to remove C5a des arg 
from the immunoadsorbent column did not affect its biological activity. This is 
consistent with the unusual structural stability of the C5a and the C5a des arg 
molecules (Hugli and Mtiller-Eberhard, 1978). 
By chemical analysis the molecular weight of C5a is approximately 11,000 daltons 
(Fernandez and Hugli, 1976). Because of its high carbohydrate content (25%), C5a 
des arg, like many glycoproteins (Segrest et al., 1971), exhibits anomalous behavior 
in SDS-PAGE. This results in an overestimation of the molecular weight. Indeed, we 
estimated the molecular weight of our preparation to be 14,600 daltons which is 
similar to the estimates of 15-16,000 daltons from SDS-PAGE determined by other 
investigators (Vallota and Mt~ller-Eberhard, 1973; Fernandez and Hugli, 1976). 
It is thought that C5a des arg is the most important and active physiological 
chemotactic factor. As such, it has been shown to elicit various pro-inflammatory 
reactions which can be either beneficial or detrimental to the host. The use of highly 
purified C5a des arg is critical for elucidating the roles and the mechanisms of action 
of this factor in these reactions as well as to rule out possible modulating effects of 
other serum proteins. Indeed, the use of purified C5a and C5a des arg has led to the 
discovery of receptors on human neutrophils (Chenoweth and Hugli, 1980) and has 
allowed for the elucidation of the intricate control mechanism for anaphylactic 
activity contained in CSa (Bokisch and Mt~ller-Eberhard, 1970; Gerard and Hugli, 
1981). 
In addition to its relative simplicity and rapidity, the purification scheme pre- 
sented in this report has other advantages. Serum depleted of C5a des arg by passage 
over the immunoadsorbent column has been substituted for untreated human serum 
in the chemotaxis under agarose assay resulting in significantly lowered random 
neutrophil migration (Manderino et al., 1981). A further advantage is that the 
antibody reacts with both C5a and C5a des arg which should allow purification of 
either molecule depending on the starting material. Lastly, the immunoadsorbent 
column can be recycled repeatedly, thus one column suffices for multiple purifica- 
tions. These attributes make this method a practical alternative to the previously 
published procedures for purifying C5a des arg or C5a. 
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